Skip to content

Real-time Engagement for Learning to Effectively Control Type 2 Diabetes

Real-time Engagement for Learning to Effectively Control Type 2 Diabetes

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06375460
Acronym
REFLECT2D
Enrollment
100
Registered
2024-04-19
Start date
2026-09-30
Completion date
2029-08-01
Last updated
2026-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2, Hyperglycemia, Lifestyle, Physical Inactivity

Brief summary

The goal of this clinical trial is to learn if a new smartphone app that pairs glucose and exercise data will help adolescents and young adults with type 2 diabetes improve glycemic control. It will also study how changes in glycemic control are maintained over time. The main questions it aims to answer are: * Does using the app help with short-term glycemic control? * Does using the app help with longer-term glycemic control? * Does using the app help increase physical activity? Participants will: * Wear a continuous glucose monitoring device for 6 months * Wear a physical activity tracker for 6 months * Use the study smartphone app for 6 months * Complete 3 in-person study visits with fasting blood draws * Report dietary intake intermittently throughout the study

Detailed description

The objective of REFLECT2D (Real-time Engagement For Learning to Effectively Control Type 2 Diabetes) is to evaluate whether pairing real-time glycemic and health behavior data leads to improved glycemic control among adolescents and young adults with type 2 diabetes. Participants will use a mobile app that integrates continuous glucose monitor data, Fitbit activity tracker data, and diet logging, with the aim of increasing capability to interpret glycemic data (including impacts of physical activity and dietary intake), providing opportunity to plan and implement behavior change, and increasing motivation to engage in health behaviors. After an initial educational session and run-in period, a 90-day micro-randomized trial (MRT) period will involve once daily randomization of each participant to: 1) physical-activity focused prompt, 2) dietary intake-focused prompt, or 3) no prompt. After the MRT, a 90-day observation period without prompts but with ongoing availability of continuous glucose monitor data, Fitbit, and Healthmine app will examine persistence of glycemic and behavior changes.

Interventions

BEHAVIORALFocused App Prompt

Prompts are designed to develop knowledge and self-efficacy in diabetes-related health behaviors (capability). The paired glycemic and behavior data will provide the opportunity to reflect and to plan diet or exercise for the following day (self-reflective motivation).

BEHAVIORALNo App Prompt

No app prompts are designed to assess whether health behaviors are affected without being prompted to reflect and change those behaviors related to glycemic control.

Sponsors

University of Pittsburgh
Lead SponsorOTHER
Dartmouth College
CollaboratorOTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
University of Michigan
CollaboratorOTHER
San Diego State University
CollaboratorOTHER
Emory University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Intervention model description

Subjects will wear a continuous glucose monitor and activity watch for study duration. Subjects will be micro-randomized once daily for 90 days to receive app prompts regarding nutrition or physical activity.

Eligibility

Sex/Gender
ALL
Age
14 Years to 26 Years
Healthy volunteers
No

Inclusion criteria

* type 2 diabetes: negative diabetes autoantibodies, no suspicion for monogenic diabetes * English-speaking (app in English)

Exclusion criteria

* Current pregnancy * Hydroxyurea use (CGM sensor inaccuracies) * Cognitive impairment or severe psychiatric condition that could interfere with participation in behavioral intervention for diabetes self-management * Current or previously diagnosed eating disorder

Design outcomes

Primary

MeasureTime frameDescription
Glucose time above 180mg/dLdaily during micro randomized trial, 90 daysmeasured using continuous glucose monitor
Mean daily glucosedaily during micro randomized trial, 90 daysmeasured using continuous glucose monitor; mg/dL
Maximum daily glucosedaily during micro randomized trial, 90 daysmeasured using continuous glucose monitor; mg/dL
Minimum daily glucosedaily during micro randomized trial, 90 daysmeasured using continuous glucose monitor; mg/dL
Glucose coefficient of variabilitydaily during micro randomized trial, 90 daysmeasured using continuous glucose monitor
Mean amplitude of glycemic excursionsdaily during micro randomized trial, 90 daysmeasured using continuous glucose monitor
Hemoglobin A1cthrough study completion, 6 months averagelab-based measure to assess longer-term glycemic control, collected at study visit
Fasting glucosethrough study completion, 6 months averagelab-based measure to assess glycemic control, collected at study visit
Objective physical activity (step count)daily during micro randomized trial, 90 days;step count measured using the Fitbit physical activity tracker
Objective physical activity (moderate-vigorous physical activity)daily during micro randomized trial, 90 days;moderate-vigorous physical activity (\>100 steps per minute) will be measured using Fitbit activity tracker
Self-reported physical activitythrough study completion, 6 months averageassessed using PACE+ Adolescent Physical Activity Measure (PACE+) questionnaire to determine days with at least 60 minutes of moderate-vigorous physical activity per week. score ranges from 0-14; lower scores indicate less achievement of physical activity guidelines
Diet qualitythrough study completion, 6 months average24-hour dietary recall will be collected by study staff, who will use the Automated Self Administered 24 Hour Dietary Recall Assessment Tool (ASA24) to record data for diet quality assessment
Capabilitythrough study completion, 6 months averageAssessed via the Diabetes Empowerment Scale (DES), a measure of self-efficacy. Average score ranges from 28-140; higher scores indicate greater diabetes empowerment
Healthmine app useduring microrandomized trial, observational periodPercent of days with app use, per study period will be determined.
Continuous glucose monitor use useduring microrandomized trial, observational periodDefined as percent of days with CGM data available, per study period.
Motivation to engage in diabetes self-managementthrough study completion, 6 months averageMeasured via Treatment Self-Regulation Questionnaire (TSRQ). score ranges from 15-105; scoring is based on and average between subscales of intrinsic vs. extrinsic motivation.

Secondary

MeasureTime frameDescription
Body Mass Index (BMI)through study completion, 6 months averageweight and height will be combined to report BMI in kg/m\^2
Diabetes distressthrough study completion; 6 months averageMeasured via Problem Areas in Diabetes Scale (PAID-5). Score ranges from 0-20; a total score of 8 or more indicates possible diabetes related emotional distress.

Countries

United States

Contacts

CONTACTMary Ellen Vajravelu, MD
vajravelume@upmc.edu412-692-6533
CONTACTMargaret Zupa, MD
zupamf@upmc.edu
PRINCIPAL_INVESTIGATORMary Ellen Vajravelu, MD

University of Pittsburgh

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 12, 2026